Community-based treatment for chronic hepatitis C in drug users: High rates of compliance with therapy despite ongoing drug use

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 1, 2009, Pages 29-37

  Wilkinson, M ^a   Crawford, V ^a   Tippet, A ^a   Jolly, F ^a   Turton, J ^a   Sims, E ^a   Hekker, M ^a   Dalton, J ^a   Marley, R ^b   Foster, G R ^b  

^a EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG USERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; PATIENT COMPLIANCE; RIBAVIRIN; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 57649202063     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03834.x     Document Type: Article

References (19)

1. Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997 26 : 794 7.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 349 : 825 32.
3. D'Souza R, Foster GR. Diagnosis and treatment of hepatitis C. J R Soc Med 2004 97 : 223 5.
4. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 5 : 124 9.
5. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007 132 : 103 12.
6. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 9.
7. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatology 1996 24 : 38 47.
8. Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004 99 : 1490 6.
9. Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001 49 (Suppl. 1 I1 21.
10. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001 345 : 211 5.
11. National Institute for Clinical Excellence. Guidance on the Use of Pegylated Interferons. London, UK : NICE, 2003.
12. Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007 45 : 111 7.
13. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001 34 : 188 93.
14. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007 22 : 1519 25.
15. Reimer J, Schulte B, Castells X, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis 2005 40 (Suppl. 5 S373 8.
16. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 352 : 2609 17.
17. D'Souza R, Glynn MJ, Ushiro-Lumb I, et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005 3 : 910 7.
18. Loguercio C, Di Pierro M, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000 35 : 296 301.
19. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.